

**MEDEXUS PHARMACEUTICALS INC.**  
**Annual and Special Meeting of Shareholders of**  
**Medexus Pharmaceuticals Inc. (the “Company”)**  
**held on**  
**Thursday, September 16, 2021**

**REPORT OF VOTING RESULTS**

*National Instrument 51-102 – Continuous Disclosure Obligations – Section 11.3*

Shareholders holding 30.14% of the issued and outstanding common shares of the Company as at the record date of August 3, 2021 were represented in person or by proxy at the meeting. The meeting was held virtually, and accordingly, voting on all matters at the meeting was conducted by ballot. All matters put to a ballot were passed with the requisite shareholder approval. The detailed results are set out below.

**Matters Voted Upon**

**Results of Ballot**

	<b><u>Votes For</u></b>	<b><u>Votes Withheld/Against</u></b>
1. The election of directors was conducted by ballot. Each of the six nominees in the Company’s management information circular dated August 6, 2021 were elected to serve until the next annual meeting of shareholders of the Company or until their successors are duly elected or appointed. The percentage of votes cast for and withheld from the vote are set forth below opposite the name of each director:		
(a) Peter van der Velden;	97.31% (3,602,083)	2.69% (99,537)
(b) Ken d’Entremont;	98.48% (3,645,332)	1.52% (56,288)
(c) Michael Mueller;	96.76% (3,581,757)	3.24% (119,863)
(d) Benoit Gravel;	97.76% (3,618,557)	2.24% (83,063)
(e) Stephen Nelson;	97.77% (3,619,057)	2.23% (82,563)
(f) Adele M. Gulfo;	98.05% (3,629,406)	1.95% (72,214)

**Matters Voted Upon****Results of Ballot**

	<b><u>Votes For</u></b>	<b><u>Votes Withheld/Against</u></b>
2. The re-appointment of PricewaterhouseCoopers LLP, as auditors of the Company for the ensuing year and the authorization of the directors to fix their remuneration as such.	99.66% (5,761,867)	0.34% (19,400)
3. The approval of the resolution to ratify, confirm and approve the amended and restated by-law no. 1 of the Company.	99.14% (3,669,770)	0.86% (31,850)
4. The approval of the amendments to the Company's amended and restated 2018 Omnibus Equity Incentive Compensation Plan.	57.04% (2,111,497)	42.96% (1,590,123)

Dated this 16<sup>th</sup> day of September, 2021.

**MEDEXUS PHARMACEUTICALS INC.**

By: (signed) "Marcel Konrad"  
Name: Marcel Konrad  
Title: Chief Financial Officer